ENTRY IN THE ADHD DRUGS MARKET: WELFARE IMPACT OF GENERICS AND ME-TOO'S*

Recent decades have seen a growth in treatments for attention deficit hyperactivity disorder (ADHD) including many branded and generic drugs. In the early 2000's, new drug entry dramatically altered market shares. We estimate a demand system for ADHD drugs and assess the welfare impact of new d...

Descripción completa

Detalles Bibliográficos
Autores principales: Bokhari, Farasat A S, Fournier, Gary M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Ltd 2013
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4373170/
https://www.ncbi.nlm.nih.gov/pubmed/25821242
http://dx.doi.org/10.1111/joie.12017
_version_ 1782363305716744192
author Bokhari, Farasat A S
Fournier, Gary M
author_facet Bokhari, Farasat A S
Fournier, Gary M
author_sort Bokhari, Farasat A S
collection PubMed
description Recent decades have seen a growth in treatments for attention deficit hyperactivity disorder (ADHD) including many branded and generic drugs. In the early 2000's, new drug entry dramatically altered market shares. We estimate a demand system for ADHD drugs and assess the welfare impact of new drugs. We find that entry induced large welfare gains by reducing prices of substitute drugs, and by providing alternative delivery mechanisms for existing molecules. Our results suggest that the success of follow-on patented drugs may come from unanticipated innovations like delivery mechanisms, a factor ignored by proposals to retard new follow-on drug approvals.
format Online
Article
Text
id pubmed-4373170
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher John Wiley & Sons Ltd
record_format MEDLINE/PubMed
spelling pubmed-43731702015-03-27 ENTRY IN THE ADHD DRUGS MARKET: WELFARE IMPACT OF GENERICS AND ME-TOO'S* Bokhari, Farasat A S Fournier, Gary M J Ind Econ Original Articles Recent decades have seen a growth in treatments for attention deficit hyperactivity disorder (ADHD) including many branded and generic drugs. In the early 2000's, new drug entry dramatically altered market shares. We estimate a demand system for ADHD drugs and assess the welfare impact of new drugs. We find that entry induced large welfare gains by reducing prices of substitute drugs, and by providing alternative delivery mechanisms for existing molecules. Our results suggest that the success of follow-on patented drugs may come from unanticipated innovations like delivery mechanisms, a factor ignored by proposals to retard new follow-on drug approvals. John Wiley & Sons Ltd 2013-06 2013-07-11 /pmc/articles/PMC4373170/ /pubmed/25821242 http://dx.doi.org/10.1111/joie.12017 Text en © 2013 The Authors. Journal of Industrial Economics published by John Wiley & Sons Ltd and the Editorial Board of The Journal of Industrial Economics http://creativecommons.org/licenses/by/3.0/ This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Original Articles
Bokhari, Farasat A S
Fournier, Gary M
ENTRY IN THE ADHD DRUGS MARKET: WELFARE IMPACT OF GENERICS AND ME-TOO'S*
title ENTRY IN THE ADHD DRUGS MARKET: WELFARE IMPACT OF GENERICS AND ME-TOO'S*
title_full ENTRY IN THE ADHD DRUGS MARKET: WELFARE IMPACT OF GENERICS AND ME-TOO'S*
title_fullStr ENTRY IN THE ADHD DRUGS MARKET: WELFARE IMPACT OF GENERICS AND ME-TOO'S*
title_full_unstemmed ENTRY IN THE ADHD DRUGS MARKET: WELFARE IMPACT OF GENERICS AND ME-TOO'S*
title_short ENTRY IN THE ADHD DRUGS MARKET: WELFARE IMPACT OF GENERICS AND ME-TOO'S*
title_sort entry in the adhd drugs market: welfare impact of generics and me-too's*
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4373170/
https://www.ncbi.nlm.nih.gov/pubmed/25821242
http://dx.doi.org/10.1111/joie.12017
work_keys_str_mv AT bokharifarasatas entryintheadhddrugsmarketwelfareimpactofgenericsandmetoos
AT fourniergarym entryintheadhddrugsmarketwelfareimpactofgenericsandmetoos

Ejemplares similares